Human growth hormone, which is also known as somatotropin is secreted by the pituitary gland and is responsible for natural spontaneous growth and metabolic activities of the human body. However, there are several human growth hormone complications as growth hormone deficiency, turner syndrome, prader-willi syndrome, idiopathic short stature and small for gestational age (SGA) that hinders the regular activities of growth hormone. In such conditions artificial growth hormone induction is necessary.
The rising incidence of human growth hormone disorders, abundance of geriatric population with the need of growth hormone treatment, developed rDNA technology etc. are some of the noteworthy causes for the fast growth of global human growth hormone market. Amongst this, the increasing incidence of human growth hormone disorder is playing the major as a market driver. A study from Pfizer UK shows that the prevalence of paediatric growth hormone deficiency in the UK is estimated to be 1 in 3500 children; treatment of this patients requires growth hormone which accelerates the market. However, factor such as side effects of artificial growth hormone and insufficient research & development fund in developing countries may hinder the growth during forecast period.
Owing to these factors the global market for human growth hormone is showing significant growth during forecast period with CAGR of ~7.1%. The human growth hormone market worldwide is estimated to generate around ~USD 6.27 billion in revenue by the end of 2025.
Some of the major firms competing in the global markets are Pfizer Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Ipsen S., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd. etc.
The natural growth hormone production reduces by 14% in the late twenties. Secretropin developed by Millennium Health Centers, Inc. may serve as an antidote to that reduction. It enhances the signal to the pituitary gland to secrete more HGH (Human Growth Hormone). It is an oral spray and this easy usability can cause widespread adoption of this technology and in the future that may enhance human growth hormone market.
Dominant region and Fastest growing region
The global human growth hormone market is dominated by North Americas region owing to increasing geriatric population and high incidences of turner syndrome. Moreover, presence of major players and government investment in research and development also fuelling the growth of human growth hormone market. However, Asia Pacific witness the fastest growing region during the forecast period owing to its booming economy and cheap production cost of growth hormone.
The market can be segmented by route of administration, application on diseases and geographical region. Route of administration includes subcutaneous, intramuscular, intravenous and oral. On basis of application, the market can be segmented into growth hormone deficiency, turner syndrome, idiopathic short stature, prader-willi syndrome, small for gestational age and others. The graph below shows the application of growth hormone as per diseases.
The market can be segmented based on their geographical area of production and consumption into North America which is dominated by USA and Canada. Europe includes UK and Germany and Asia Pacific includes emerging economies as China and India.